Orphan Drug Makers Get Selected Tax Breaks As China Turns To Access
Following anticancer drugs, rare disease treatments become the latest products in China’s to get value added tax reductions. Orphan drug makers can breath easier, but much more is needed, industry insiders say.
You may also be interested in...
As a promising market for orphan drugs, China has seen several approvals in this space in the past six months, mostly from multinationals. But Beijing-based CANbridge believes that a smaller biotech also has a good shot at a leadership role, despite a lack of funding and reimbursement and prickly pricing issues.
A new national security law passed by China is expected to bring an uncertain future to many health companies eyeing a possible listing in Hong Kong.
More countries are joining the US to put national security interests over globalization, moving the production of medicines, medical supplies and protective equipment closer to home. The calls to repatriate manufacturing and reduce reliance on China will profoundly change how health products are supplied worldwide in the post-coronavirus era.